Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: A focused safety analysis of ACTG PEARLS (A5175)

by Touzard Romo,F., Smeaton,L.M., Campbell,T.B., Rivière,C., Mngqibisa,R., Nyirenda,M.J., Supparatpinyo,K., Kumarasamy,N., Hakim,J.G., Flanigan,T.P.
Published 2015

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

by Campbell T., Smeaton L., Kumarasamy N., Flanigan T., Klingman K., Firnhaber C., Grinsztejn B., Hosseinipour M., Kumwenda J., Lalloo U., Riviere C., Sanchez J., Melo M., Supparatpinyo K., Tripathy S., Martinez A., Nair A., Walawander A., Moran L., Chen Y., Snowden W., Rooney J., Uy J., Schooley R., de Gruttola V., Hakim J., Swann E., Barnett R., Brizz B., Delph Y., Gettinger N., Mitsuyasu R., Eshleman S., Safren S., Fiscus S., Andrade A., Haas D., Amod F., Berthaud V., Bollinger R., Bryson Y., Celentano D., Chilongozi D., Cohen M., Collier A., Currier J., Cu-Uvin S., Eron J., Flexner C., Gallant J., Gulick R., Hammer S., Hoffman I., Kazembe P., Kumwenda N., Lama J., Lawrence J., Maponga C., Martinson F., Mayer K., Nielsen K., Pendame R., Ramratnam B., Sanne I., Severe P., Sirisanthana T., Solomon S., Tabet S., Taha T., van der Horst C., Wanke C., Gormley J., Marcus C., Putnam B., Ntshele S., Loeliger E., Pappa K., Webb N., Shugarts D., Winters M., Descallar R., Steele J., Wulfsohn M., Said F., Chen Y., Martin J., Bischofberger N., Cheng A., Jaffe H., Sharma J., Poongulali S., Cardoso S., Faria D., Berendes S., Burke K., Mngqibisa R., Kanyama C., Kayoyo V., Samaneka W., Chisada A.
Published 2017